Get started
Author

Marion E. Morrison

Observed names: M. Morrison, Marion Morrison, Morrison, Marion E.
ORCID: 0000-0003-2060-0866
Observed ORCID: 0000-0003-2060-0866
OpenAlex ID: A5069222476
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation
2018 · Francisco M. Marty, Drew J. Winston, et al. · Transplantation and Cellular Therapy · 219
Brincidofovir for Asymptomatic Adenovirus Viremia in Pediatric and Adult Allogeneic Hematopoietic Cell Transplant Recipients: A Randomized Placebo-Controlled Phase II Trial
2017 · Michael S. Grimley, Roy F. Chemaly, et al. · Transplantation and Cellular Therapy · 168
PDF
Short-term clinical safety profile of brincidofovir: A favorable benefit–risk proposition in the treatment of smallpox
2017 · Greg Chittick, Marion Morrison, et al. · Antiviral Research · 130
Brincidofovir Is Not a Substrate for the Human Organic Anion Transporter 1: A Mechanistic Explanation for the Lack of Nephrotoxicity Observed in Clinical Studies
2016 · Timothy K. Tippin, Marion E. Morrison, et al. · Therapeutic Drug Monitoring · 79
Brincidofovir for Prevention of Cytomegalovirus (CMV) after Allogeneic Hematopoietic Cell Transplantation (HCT) in CMV-Seropositive Patients: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Trial
2016 · Francisco M. Marty, Drew J. Winston, et al. · Transplantation and Cellular Therapy · 38
Design and Rationale of a Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study Evaluating Dociparstat in Acute Lung Injury Associated with Severe COVID-19
2020 · Joseph A. Lasky, Jyotsna Fuloria, et al. · Advances in Therapy · 21
PDF
Establishment of the 1st International Genetic Reference Panel for Factor V Leiden, human gDNA
2006 · J. Hawkins, Marion Morrison, et al. · Thrombosis and Haemostasis · 13
Pharmacokinetics (PK) and Safety of Intravenous (IV) Brincidofovir (BCV) in Healthy Adult Subjects
2017 · Mary Beth Wire, Marion Morrison, et al. · Open Forum Infectious Diseases · 11
A Phase 1 Randomized Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Escalating Oral Doses of Dordaviprone and the Effects of Food on the Bioavailability of Dordaviprone in Healthy Adult Subjects
2025 · Shamia L. Faison, Joelle Batonga, et al. · Clinical Pharmacology in Drug Development · 9
PDF
A phase 1, randomized, crossover trial to assess the effect of itraconazole on the pharmacokinetics of dordaviprone in healthy adults
2025 · Shamia L. Faison, Joelle Batonga, et al. · British Journal of Clinical Pharmacology · 5
1421. IV Brincidofovir (BCV): Pharmacokinetics (PK) and Safety of Multiple Ascending Doses (MAD) in Healthy Subjects
2018 · Odin Naderer, Virna Schuck, et al. · Open Forum Infectious Diseases · 5
A Phase 1 Study to Evaluate the Absorption, Metabolism, and Disposition of Dordaviprone in Healthy Adult Participants
2025 · Yohannes Teffera, Tim Tippin, et al. · Clinical Pharmacology in Drug Development · 4
PDF
Relative Bioavailability of Dordaviprone (ONC201) is Not Affected by Co‐Administration of the Proton‐Pump Inhibitor Rabeprazole
2024 · Shamia L. Faison, Joelle Batonga, et al. · The Journal of Clinical Pharmacology · 3
Effect of Severe Renal Impairment on Dordaviprone (ONC201) Pharmacokinetics
2025 · Shamia L. Faison, Joelle Batonga, et al. · Drugs in R&D · 2
PDF
Switch From Existing Antivirals to Brincidofovir Leads to Improving Renal Function.
2014 · M. Morrison, R. Avery, et al. · Transplantation · 2
A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Dordaviprone
2025 · Shamia L. Faison, Joelle Batonga, et al. · The Journal of Clinical Pharmacology
Ncog-07. Safety of Onc201 Treatment in Patients With Previously Treated H3 K27m-mutant Glioma: Results From Onc028, an Ongoing Compassionate Use Program
2024 · Akansha Sharma, Robert Aiken, et al. · Neuro-Oncology
PDF
Works count: 18
Citation count: 709
H-index: 9
I10-index: 8
Year
Topic
Type